SEPTIN9 and colorectal carcinoma: In 2016 the FDA approved as a screening tool the Epi proColon Kit version 1.0 (which later was upgraded to version 2.0) that detects SEPT9 promotor region methylation in plasma-originated tumour DNA, which is considered to be a specific biomarker of early CRC stages [119,120].